Eclipsebio is pleased to announce the 2026 mRNA Innovators Award to support early-stage innovation in mRNA-based drug development. 

The mRNA Innovators Award offers matching funds to support early-stage RNA drug developers* in the design and validation of a novel mRNA-based therapeutic using Eclipsebio’s mRNA drug discovery platform. 

As an awardee, our RNA therapeutics success team will design, prototype, and validate your therapeutic of interest using our design models and trusted RNA characterization methods. You will receive an aliquot of the mRNA for additional testing. In addition, you will maintain full ownership of the developed therapeutic with no requirements for licensing or royalties.  

With this award, Eclipsebio furthers its commitment to enabling high-impact RNA research and providing early-stage drug developers with the same RNA design and characterization assays trusted by established therapeutic developers. 

Interested early-stage RNA drug developers should fill out the form accessed from the button below. You will be asked in the application to submit a brief description of your therapeutic goals. If you pass the initial review, you will meet with our design team to review your project in more detail before the final selection. 

For any questions about the mRNA Innovators Award, application process, or how Eclipsebio supports our partners in their research and drug discovery programs, you can contact us at info@eclipsebio.com. 

*To support early-stage innovation, this competition is only available to academic researchers or companies with pre-seed or seed-stage funding.